Get the Weekly Intelligence Brief — top committee picks every Sunday.

EXEL vs SGRY

Exelixis vs Surgery Partners, Inc. — AI-powered side-by-side comparison
EXEL
Exelixis
67
Buy
VS
SGRY
Surgery Partners, Inc.
48
Watch
MetricEXELSGRY
AI Score 67 48
Price $51.30 $15.02
P/E Ratio 15.60× -21.74×
ROE 36.2% -4.5%
Revenue Growth YoY
Gross Margin 96.5% 21.4%
Debt / Equity 0.09× 2.40×
Dividend Yield 0.0% 0.0%
RSI (14) 41.0 42.3
Beta 0.422 1.937
Expected Upside +8.7%

AI Committee View

Current Innellis committee reasoning for EXEL versus SGRY.
EXEL leads by 19 points.

EXEL scores 67/100 (Buy) versus SGRY at 48/100 (Watch).

EXEL Committee View
67% agreement
6 analysts

The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.

Bull Case
  • ROE of 42.5% shows genuine earnings power backing the valuation — Value
  • EPS growing 52.7% YoY — Growth
  • 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
  • Price-to-book of 5.4x prices in significant intangible value — Value
  • MACD histogram negative -- bearish momentum — Technical
SGRY Committee View
33% agreement
6 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -20.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Price-to-book of 1.2x is a discount to asset value — Value
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • ROE of only -4.6% -- cheap may mean cheap for a reason — Value
  • Debt-to-equity of 2.16 adds balance-sheet risk to the value case — Value
  • Revenue declining -20.5% YoY -- this is not a growth story right now — Growth
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
EXEL Full Analysis SGRY Full Analysis